Form 4: Immuneering Director Boosts Stake with 7,500 Share Purchase

Immuneering Corp. Director Peter Feinberg increased his stake by acquiring 7,500 shares of Class A Common Stock at a weighted average price of $7.0307.

Summary

• Peter Feinberg, a Director of Immuneering Corp. (IMRX), purchased 7,500 shares of Class A Common Stock.
• The transaction occurred on September 30, 2025, at a weighted average price of $7.0307 per share.
• The purchase price ranged from $7.0049 to $7.055 across multiple trades through a broker-dealer.
• Following this transaction, Peter Feinberg directly owns 149,266 shares of Class A Common Stock.
• He also indirectly beneficially owns 392,242 shares as General Partner of PF Associates L.P., 476,615 shares as General Partner of PEF LLC., and 115,441 shares as General Partner of S4K Investments LLC.
• His total beneficial ownership after the transaction is 1,133,564 shares.

Sentiment

Score: 8

Explanation: The purchase of company stock by a director is generally viewed as a strong positive signal, indicating confidence in the company's future prospects and valuation.

Positives

• A Director's purchase of company stock signals confidence in the company's future prospects and valuation.
• The acquisition increases the Director's direct stake, aligning his interests further with shareholders.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider buying, particularly by a director, is often interpreted by the market as a positive signal, indicating that those with intimate knowledge of the company believe its stock is undervalued or that significant positive developments are anticipated. This transaction aligns the director's financial interests more closely with those of other shareholders.

Stakeholder Impact

• Shareholders may perceive this insider purchase as a vote of confidence from a director, potentially leading to increased investor interest and positive sentiment towards the stock.
• The increased alignment of the director's financial interests with those of other shareholders could be seen as beneficial for corporate governance.

Key Dates

Recommendation

The acquisition of 7,500 shares by a Director at market price signals strong insider confidence in Immuneering Corp.'s future performance and valuation. Such a move by a key insider often precedes positive developments or indicates a belief that the stock is currently undervalued, making it a compelling 'buy' signal for investors.

Keywords

Immuneering Corp, IMRX, Peter Feinberg, Insider Trading, Form 4, Stock Purchase, Director, Beneficial Ownership, Equity Acquisition